deltatrials
Recruiting PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT06590324

A Study of Apabetalone in Subjects With Long -COVID

A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)

Sponsor: Resverlogix Corp

Conditions Post-Acute COVID-19 Syndrome
Interventions Apabetalone
Updated 2 times since 2024 Last updated: Apr 15, 2025 Started: Apr 15, 2025 Primary completion: Dec 30, 2025 Completion: Mar 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06590324, this PHASE2/PHASE3 trial focuses on Post-Acute COVID-19 Syndrome and remains actively recruiting participants. Sponsored by Resverlogix Corp, it has been updated 2 times since 2025, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Oct 2024 – ~May 2025 · 7 months · monthly snapshotNot Yet Recruiting~May 2025 – present · 14 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. May 2025 — Present [monthly]

    Recruiting PHASE2/PHASE3

    Status: Not Yet Recruiting → Recruiting

  2. Oct 2024 — May 2025 [monthly]

    Not Yet Recruiting PHASE2/PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Resverlogix Corp
Data source: Resverlogix Corp

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations